Compare Twist Bioscience Corp (TWST) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs 22nd Century Group Inc — how do they compare? Twist Bioscience Corp trades at $159.78 (market cap $10.08B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Twist Bioscience Corp is far larger — about 16214.4× 22nd Century Group Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and 22nd Century Group Inc for 32 Days on average.
| TWST | XXII | |
|---|---|---|
Market Cap | $10.08B | $621.67K |
Volume | 4,229,037 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $205.00 | $483.00 |
52-Week Low | $25.45 | $0.80 |
Typical Hold Time | 27 Days | 32 Days |
Enterprise Value | $10.01B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
